Statin Effects to Reduce Hepatosteatosis as Measured by Computed Tomography in Patients With Human Immunodeficiency Virus | Zendy

Janet Lo | Zendy; Michael T. Lu | Zendy; Elli A. Kim | Zendy; Eric Nou | Zendy; Travis R. Hallett | Zendy; Jakob Park | Zendy; Udo Hoffmann | Zendy; Steven Grinspoon | Zendy

Open Access

Statin Effects to Reduce Hepatosteatosis as Measured by Computed Tomography in Patients With Human Immunodeficiency Virus

Author(s) -

Janet Lo,

Michael T. Lu,

Elli A. Kim,

Eric Nou,

Travis R. Hallett,

Jakob Park,

Udo Hoffmann,

Steven Grinspoon

Publication year - 2016

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofw062

Subject(s) - medicine , atorvastatin , statin , nonalcoholic fatty liver disease , human immunodeficiency virus (hiv) , fatty liver , placebo , gastroenterology , randomized controlled trial , disease , immunology , pathology , alternative medicine

Hepatosteatosis is highly prevalent among patients living with human immunodeficiency virus. In a 1-year, randomized, double-blind trial of atorvastatin or placebo, atorvastatin increased liver/spleen ratio among patients with nonalcoholic fatty liver disease, indicating a reduction in hepatosteatosis. This reduction in hepatosteatosis is associated with reduction in low-density lipoprotein cholesterol with statin therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research